Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8853-8862

  Mendrzyk, Frank ^a   Radlwimmer, Bernhard ^a   Joos, Stefan ^a   Kokocinski, Felix ^a   Benner, Axel ^a   Stange, Daniel E ^a   Neben, Kai ^a   Fiegler, Heike ^a   Carter, Nigel P ^a   Reifenberger, Guido ^a   Korshunov, Andrey ^a   Lichter, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 6; LOMUSTINE; PROTEIN PPM1D; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2C;

ARTICLE; CHROMOSOME 17; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; BIOSYNTHESIS; CEREBELLUM TUMOR; CHROMOSOME ABERRATION; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIVARIATE ANALYSIS; SURVIVAL;

CEREBELLAR NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CYCLIN-DEPENDENT KINASE 6; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MEDULLOBLASTOMA; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEIN PHOSPHATASE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 31544450175     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.8589     Document Type: Article

References (69)

1. Gurney JG, Kadan-Lottick N: Brain and other central nervous system tumors: Rates, trends, and epidemiology. Curr Opin Oncol 13: 160-166, 2001
2. Fisher PG, Burger PC, Eberhart CG: Biologic risk stratification of medulloblastoma: The real time is now. J Clin Oncol 22:971-974, 2004
3. Eberhart CG, Kepner JL, Goldthwaite PT, et al: Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94:552-560, 2002
4. Giangaspero F, Perilongo G, Fondelli MP, et al: Medulloblastoma with extensive nodularity: A variant with favorable prognosis. J Neurosurg 91:971-977, 1999
5. Giangaspero F, Rigobello L, Badiali M, et al: Large-cell medulloblastomas: A distinct variant with highly aggressive behavior. Am J Surg Pathol 16:687-693, 1992
6. Brown HG, Kepner JL, Perlman EJ, et al: "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59:857-865, 2000
7. Zeltzer PM, Boyett JM, Finlay JL, et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17:832-845, 1999
8. Gilbertson R: Paediatric embryonic brain tumours: Biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 38:675-685, 2002
9. Wechsler-Reya RJ: Analysis of gene expression in the normal and malignant cerebellum. Recent Prog Horm Res 58:227-248, 2003
10. Bayani J, Zielenska M, Marrano P, et al: Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 93:437-448, 2000
11. Pan E, Pellarin M, Holmes E, et al: Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 11:4733-4740, 2005
12. Nicholson JC, Ross FM, Kohler JA, et al: Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer 80:1322-1331, 1999
13. Reardon DA, Michalkiewicz E, Boyett JM, et al: Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 57:4042-4047, 1997
14. Avet-Loiseau H, Venuat AM, Terrier-Lacombe MJ, et al: Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer 79:1843-1847, 1999
15. Schutz BR, Scheurlen W, Krauss J, et al: Mapping of chromosomal gains and losses in primitive neuroectodermal tumors by comparative genomic hybridization. Genes Chromosomes Cancer 16:196-203, 1996
16. Gilhuis HJ, Anderl KL, Boerman RH, et al: Comparative genomic hybridization of medulloblastomas and clinical relevance: Eleven new cases and a review of the literature. Clin Neurol Neurosurg 102:203-209, 2000
17. Eberhart CG, Kratz JE, Schuster A, et al: Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12:36-44, 2002
18. Hui AB, Takano H, Lo KW, et al: Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis. Clin Cancer Res 11:4707-4716, 2005
19. Lamont JM, McManamy CS, Pearson AD, et al: Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493, 2004
20. Lichter P, Joos S, Bentz M, et al: Comparative genomic hybridization: Uses and limitations. Semin Hematol 37:348-357, 2000
21. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al: Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20:399-407, 1997
22. Pinkel D, Segraves R, Sudar D, et al: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207-211, 1998
23. Schwaenen C, Nessling M, Wessendorf S, et al: Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 101:1039-1044, 2004
24. Zielinski B, Gratias S, Toedt G, et al: Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 43:294-301, 2005
25. Giangaspero F, Bigner SH, Kleihues P, et al: Medulloblastoma, in Cavanee WK, Kleihues P (eds): Pathology and Genetics of Tumours of the Nervous System. Lyons, France, IARC Press, 2000, pp 129-137
26. Kortmann RD, Kuhl J, Timmermann B, et al: Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46:269-279, 2000
27. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
28. Fiegler H, Carr P, Douglas EJ, et al: DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 36:361-374, 2003
29. Knight SJ, Lese CM, Precht KS, et al: An optimized set of human telomere clones for studying telomere integrity and architecture. Am J Hum Genet 67:320-332, 2000
30. Freier K, Joos S, Flechtenmacher C, et al: Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 63:1179-1182, 2003
31. Waye JS, England SB, Willard HF: Genomic organization of alpha satellite DNA on human chromosome 7: Evidence for two distinct alphoid domains on a single chromosome. Mol Cell Biol 7:349-356, 1987
32. Bubendorf L, Kononen J, Koivisto P, et al: Survey of gene amplifications during prostate cancer progression by higb-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806, 1999
33. Lichter P, Cremer T, Borden J, et al: Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. Hum Genet 80:224-234, 1988
34. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45, 2001
35. Harrell FE Jr, Shih YC: Using full probability models to compute probabilities of actual interest to decision makers. Int J Technol Assess Health Care 17:17-26, 2001
36. de Hoon MJ, Imoto S, Nolan J, et al: Open source clustering software. Bioinformatics 20:1453-1454, 2004
37. Fan X, Wang Y, Kratz J, et al: HTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol 162:1763-1769, 2003
38. Adesina AM, Nalbantoglu J, Cavenee WK: p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 54:5649-5651, 1994
39. Biegel JA, Burk CD, Barr FG, et al: Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 52:3391-3395, 1992
40. Di Marcotullio L, Ferretti E, De Smaele E, et al: REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci U S A 101:10833-10838, 2004
41. Koch A, Tonn J, Kraus JA, et al: Molecular analysis of the lissencephaly gene 1 (LIS-1) in medulloblastomas. Neuropathol Appl Neurobiol 22:233-242, 1996
42. McDonald JD, Daneshvar L, Willert JR, et al: Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. Genomics 23:229-232, 1994
43. Ohgaki H, Eibl RH, Schwab M, et al: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8:74-80, 1993
44. Wu X, Senechal K, Neshat MS, et al: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95:15587-15591, 1998
45. Neben K, Korshunov A, Benner A, et al: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64:3103-3111, 2004
46. Oliver TG, Grasfeder LL, Carroll AL, et al: Transcriptional profiling of the Sonic hedgehog response: A critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A 100:7331-7336, 2003
47. Saito-Ohara F, Imoto I, Inoue J, et al: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63:1876-1883, 2003
48. Li J, Yang Y, Peng Y, et al: Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 31:133-134, 2002
49. Hirasawa A, Saito-Ohara F, Inoue J, et al: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9:1995-2004, 2003
50. Bulavin DV, Demidov ON, Saito S, et al: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31:210-215, 2002
51. Bulavin DV, Phillips C, Nannenga B, et al: Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36:343-350, 2004
52. Takekawa M, Adachi M, Nakahata A, et al: p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. Embo J 19:6517-6526, 2000
53. Portwine C, Chilton-MacNeill S, Brown C, et al: Absence of germline and somatic p53 alterations in children with sporadic brain tumors. J Neurooncol 52:227-235, 2001
54. Moro T, Ogasawara T, Chikuda H, et al: Inhibition of Cdk6 expression through p38 MAP kinase is involved in differentiation of mouse prechondrocyte ATDC5. J Cell Physiol 204:927-933, 2005
55. Chilosi M, Doglioni C, Yan Z, et al: Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol 152:209-217, 1998
56. Costello JF, Plass C, Arap W, et al: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 57:1250-1254, 1997
57. Ortega S, Malumbres M, Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73-87, 2002
58. Zindy F, Nilsson LM, Nguyen L, et al: Hemangiosarcomas, medullobiastomas, and other tumors in Ink4c/p53-null mice. Cancer Res 63:5420-5427, 2003
59. Wetmore C, Eberhart DE, Curran T: Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 61:513-516, 2001
60. Marino S, Vooijs M, van Der Gulden H, et al: Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 14:994-1004, 2000
61. Dyer MA: Mouse models of childhood cancer of the nervous system. J Clin Pathol 57:561-576, 2004
62. Faast R, White J, Cartwright P, et al: Cdk6-cyclin D3 activity in murine ES cells is resistant to inhibition by p16(INK4a). Oncogene 23:491-502, 2004
63. Matushansky I, Radparvar F, Skoultchi AI: CDK6 blocks differentiation: Coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene 22:4143-4149, 2003
64. Eberhart CG, Kratz J, Wang Y, et al: Histopathological and molecular prognostic markers in medulloblastoma: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441449, 2004
65. Gajjar A, Hernan R, Kocak M, et al: Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22:984-993, 2004
66. Grotzer MA, Hogarty MD, Janss AJ, et al: MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433, 2001
67. Gilbertson RJ, Clifford SC: PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 35:197-198, 2003
68. MacDonald TJ, Brown KM, LaFleur B, et al: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29:143-152, 2001
69. Fry DW, Harvey PJ, Keller PR, et al: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427-1438, 2004